SYNTHENA

Synthena AG is a development stage biotechnology company aiming to develop and commercialize new life saving drugs for the treatment of severe neuromuscular diseases based on the modulation of RNA. Its proprietary tricyclo-DNA technology platform offers broad advantages over state of the art oligonucleotide chemistries for new RNA intervention strategies like splice switching, and other antisense approaches. Its most advanced preclinical drug development program focuses on Duchenne Muscular Dystrophy, a genetic disorder which affects 1/3,500 boys and which leads to death in early adulthood... TcDNA, developed and patented by SYNTHENA AG, is currently used by other companies to design AONs targeting Duchenne disease and many other diseases of genetic origin... Synthena's mission is to develop first in class drugs in the field of Myopathy with a focus on the Duchenne Muscular Dystrophy disease, based on its proprietary tricyclo-DNA technology.

Also known as: Synthena AG

Primary location: Bern Switzerland